Protein-based biomarkers in pulmonary malignancies

Targeted therapies have revolutionised the management of patients with lung cancer over the last 20 years. A crucial role for pulmonary pathologists  is to provide high quality and timely analysis of predictive biomarkers that guide the use of these targeted treatments. Protein-based biomarkers, alongside nucleic acid analyses, are mostly used to predict response to therapies that inhibit oncogenic stimulation or utilise immune checkpoint inhi bition. Despite the protein-based mechanism of action of targeted therapies, development of biomarkers for lung cancers have been chiefly focused on genomics.
Source: Diagnostic Histopathology - Category: Pathology Authors: Tags: Mini-symposium: thoracic pathology Source Type: research